SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Analysis of Sex-Specific Cardiovascular Outcomes
Among HFrEF patients treated with SGLT2is, males experienced lower risks of HF events, hospitalizations, and renal failure compared to females, despite similar mortality. Further research is needed to understand and address sex-specific disparities in HFrEF management.
Authors
- Kwan Lee (ORCID: https://orcid.org/0000-0001-6302-9925)
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
- Beani Forst
- Hoang Nhat Pham (ORCID: https://orcid.org/0000-0001-8412-0082)
- Julie Rosenthal (ORCID: https://orcid.org/0000-0001-7002-9595)
- Ramzi Ibrahim (ORCID: https://orcid.org/0009-0003-1690-3845)
- Reza Arsanjani (ORCID: https://orcid.org/0000-0001-7081-4286)
- Patrick Sarkis
- Mahmoud Hassan Abdelnabi (ORCID: https://orcid.org/0000-0001-8016-9049)
- Hashim M. AlHammouri (ORCID: https://orcid.org/0009-0003-6314-2620)
- Rahmeh Al-Asmar
- Steven J. Lester
Institutions
- University of Jordan (JO)
- Mayo Clinic (US)
- University of Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Current Cardiology Reviews
- Published
- 2025-10-02
- DOI
- https://doi.org/10.2174/011573403x394902250911111958
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00